Cancer Research Campaign Technology Limited

Cancer Research Technology Limited

Gareth Haydn Williams

Ronald Alfred Laskey

Nicholas Coleman

Torsten Krude

Anthony David Mills

Kal Stoeber

Determination of cellular growth abnormality, particularly cancerous abnormality, by detection of target polypeptides or encoding mRNA, where the target polypeptides are members of the preinitiation complex of DNA replication in tissue, cells or fluid. Target polypeptides include CDC6, MCM2, MCM3, MCM4, MCM5, MCM6 and MCM7. Test samples include tissue of the cervix (both biopsy and smear samples), breast, colon, lung, bladder, skin, larynx, oesophagus, bronchus, lymph nodes and urinary tract (both biopsy and cytology smear samples), in determination of cancerous and pre-cancerous cellular growth abnormality, and cells spun from urine, blood and serum, in determination of haematological malignancies and evidence of metastatic sarcoma and carcinoma.

Detection of dysplastic or neoplastic cells using anti-MCM4 antibodies

The invention relates to improvements in cell-free systems for initiating DNA replication under cell cycle control. The system comprises a synchronous population of G1 nuclei which have been released from G0; and S phase cytosol. In a preferred aspect, a polypeptide is supplied to the system, wherein the polypeptide is Cdc6 and/or at least one MCM protein. The system is suitable for DNA replication assays, for example to test substances which modulate DNA replication.

Cell-free replication system and uses thereof

Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies

Growing community of inventors

Cambridge, United Kingdom

Gareth Haydn Williams